Hugh Mostafid

805 total citations · 1 hit paper
26 papers, 345 citations indexed

About

Hugh Mostafid is a scholar working on Surgery, Urology and Biotechnology. According to data from OpenAlex, Hugh Mostafid has authored 26 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 9 papers in Urology and 5 papers in Biotechnology. Recurrent topics in Hugh Mostafid's work include Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (15 papers) and Urological Disorders and Treatments (8 papers). Hugh Mostafid is often cited by papers focused on Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (15 papers) and Urological Disorders and Treatments (8 papers). Hugh Mostafid collaborates with scholars based in United Kingdom, Netherlands and Italy. Hugh Mostafid's co-authors include Luca Afferi, Stephen B. Williams, Angela B. Smith, Shilpa Gupta, Yair Lotan, Niyati Lobo, Sarah P. Psutka, Marco Moschini, Sima P. Porten and Nikhil Mayor and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Hugh Mostafid

25 papers receiving 342 citations

Hit Papers

Epidemiology, Screening, and Prevention of Bladder Cancer 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology, Screening, and Prevention of Bladder Cancer
    2022 159 citations Niyati Lobo, Luca Afferi et al. European Urology Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hugh Mostafid United Kingdom 8 274 85 79 69 63 26 345
M. Babjuk Czechia 14 352 1.3× 106 1.2× 94 1.2× 90 1.3× 102 1.6× 28 478
Christien Caris Netherlands 9 269 1.0× 111 1.3× 51 0.6× 136 2.0× 114 1.8× 21 439
Joseph Scattergood United States 5 209 0.8× 47 0.6× 92 1.2× 77 1.1× 60 1.0× 7 304
Chih‐Hsiung Kang Taiwan 9 286 1.0× 60 0.7× 47 0.6× 81 1.2× 113 1.8× 17 377
G. Zampa Italy 9 223 0.8× 104 1.2× 49 0.6× 110 1.6× 39 0.6× 41 361
Angela Qu United States 6 232 0.8× 49 0.6× 63 0.8× 93 1.3× 99 1.6× 18 301
Aleksandra Klim United States 8 181 0.7× 80 0.9× 73 0.9× 38 0.6× 74 1.2× 12 321
Ruth Knüchel‐Clarke Germany 11 130 0.5× 44 0.5× 51 0.6× 74 1.1× 70 1.1× 39 283
Armine K. Smith United States 9 424 1.5× 171 2.0× 73 0.9× 90 1.3× 128 2.0× 27 541
F. Attisani Italy 6 198 0.7× 127 1.5× 167 2.1× 29 0.4× 60 1.0× 18 399

Countries citing papers authored by Hugh Mostafid

Since Specialization
Citations

This map shows the geographic impact of Hugh Mostafid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugh Mostafid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugh Mostafid more than expected).

Fields of papers citing papers by Hugh Mostafid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugh Mostafid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugh Mostafid. The network helps show where Hugh Mostafid may publish in the future.

Co-authorship network of co-authors of Hugh Mostafid

This figure shows the co-authorship network connecting the top 25 collaborators of Hugh Mostafid. A scholar is included among the top collaborators of Hugh Mostafid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugh Mostafid. Hugh Mostafid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lobo, Niyati, Luca Afferi, Marco Moschini, et al.. (2022). Epidemiology, Screening, and Prevention of Bladder Cancer. European Urology Oncology. 5(6). 628–639. 159 indexed citations breakdown →
2.
3.
Teoh, Jeremy Yuen‐Chun, et al.. (2021). En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. World Journal of Urology. 39(9). 3353–3358. 17 indexed citations
4.
Hendricksen, Kees, et al.. (2021). Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 40(2). 62.e13–62.e20. 28 indexed citations
5.
Mayor, Nikhil, Christian D. Fankhauser, Vijay Sangar, & Hugh Mostafid. (2021). Management of NMIBC during BCG shortage and COVID‐19. Trends in Urology & Men s Health. 12(1). 7–11. 4 indexed citations
6.
Fankhauser, Christian D., Marian S. Wettstein, Luca Afferi, Nico C. Grossmann, & Hugh Mostafid. (2021). En Bloc Resection of Bladder Tumor—Is It the Way Forward?. Frontiers in Surgery. 8. 685506–685506. 3 indexed citations
7.
Lotan, Yair, Georgios Gakis, Matteo Manfredi, et al.. (2021). Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. Bladder Cancer. 7(3). 307–315. 3 indexed citations
8.
9.
Mayor, Nikhil, et al.. (2020). Localised amyloidosis of the bladder. International Journal of Surgery Case Reports. 77(C). 708–710. 1 indexed citations
10.
Mostafid, Hugh, Núria Porta, Jo Cresswell, et al.. (2019). 12 month results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk (LR) non-muscle invasive bladder cancer (NMIBC). European Urology Supplements. 18(1). e762–e763. 1 indexed citations
11.
Mostafid, Hugh, Jo Cresswell, T.R. Leyshon Griffiths, et al.. (2018). Results of CALIBER: A phase II randomised feasibility trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer. European Urology Supplements. 17(2). e1062–e1063. 1 indexed citations
12.
13.
Hendricksen, Kees, et al.. (2018). PD66-11 HYPERTHERMIC INTRAVESICAL CHEMOTHERAPY FOR BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. The Journal of Urology. 199(4S). 1 indexed citations
14.
15.
Pandha, Hardev, Nicola Annels, Hugh Mostafid, et al.. (2016). Phase I/II CANON study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21. Annals of Oncology. 27. vi361–vi361. 5 indexed citations
16.
Pandha, Hardev, Nicola Annels, Guy R. Simpson, et al.. (2016). Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. Journal of Clinical Oncology. 34(15_suppl). e16016–e16016. 7 indexed citations
17.
Swinn, M., et al.. (2016). Increasing hospital volume improves outcomes of robotic assissted radical cystectomy: Lessons learned from the first 120 cases of new service. European Urology Supplements. 15(7). 230–230. 1 indexed citations
18.
Annels, Nicola, Guy R. Simpson, David Mansfield, et al.. (2015). Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21. Journal for ImmunoTherapy of Cancer. 3(S2). 5 indexed citations
19.
Kelly, Jeffery W., et al.. (2015). HYMN: a randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of BCG or institutional standard in patients with recurrence of non-muscle invasive bladder cancer (NMIBC) following induction or maintenance BCG therapy. 3 indexed citations
20.
Mostafid, Hugh. (2009). Management of bladder cancer. 14(5). 10–15. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Babjuk Breakdown of academic impact, for papers by Christien Caris Breakdown of academic impact, for papers by Joseph Scattergood Breakdown of academic impact, for papers by Chih‐Hsiung Kang Breakdown of academic impact, for papers by G. Zampa Breakdown of academic impact, for papers by Angela Qu Breakdown of academic impact, for papers by Aleksandra Klim Breakdown of academic impact, for papers by Ruth Knüchel‐Clarke Breakdown of academic impact, for papers by Armine K. Smith Breakdown of academic impact, for papers by F. Attisani
Rankless by CCL
2026